Events

Using AI to track down potential COVID-19 treatments with Peter Richardson

Epidemiologists have drawn some parallels between the 1918 flu pandemic and today’s COVID-19 crisis. But today’s disease-fighters have powerful AI tools scientists in the early 20th century could never have imagined.

At BenevolentAI, a small specialist team of experienced drug discoverers used our state-of-the-art machine learning models and tools to query cellular processes subverted by viruses, to understand the (druggable) regulatory mechanisms involved, and then to identify approved anti-inflammatory drugs which control these processes.  Peter Richardson, our VP of Pharmacology who headed up this research, will join a panel of experts to explore the possibilities—and the progress so far— of taking AI to the coronavirus fight. 

Join the Fierce AI Week —> https://www.fierceartificialintelligence.com/


Peter Richardson

VP Pharmacology

Peter Richardson serves as VP Pharmacology at BenevolentAI. He was a founding member of Cambridge Biotechnology Ltd in 2001 and served as CSO and Executive Director until 2005. Peter pioneered the sale of CBT to Proximagen Ltd, to whom he acted as an adviser until 2012. Between 1989 and 2006 he served as a Lecturer and Senior Lecturer in the Department of Pharmacology, University of Cambridge where he pioneered research into drug discovery for Parkinson’s disease and inflammation, as well as new gene expression technologies. He is the author of over 70 peer-reviewed scientific papers. Peter studied Biochemistry at the University of Oxford, and was awarded a doctorate in Biochemistry from the University of Cambridge.

More Posts

You Might Also Like

News
Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022
News
Analyst / Investor Event
BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.
Sep 27, 2022
Blog
Building the data foundations to accelerate drug discovery
Mark Davies, BenevolentAI’s SVP Informatics and Data, discusses innovations that enable BenevolentAI to leverage biomedical data in drug discovery.
Sep 22, 2022
News
Analyst / Investor Event and Interim Results
BenevolentAI is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 – 17:00 BST (09:00 – 12:00 ET) on Tuesday, 27 September 2022.
Sep 16, 2022
Video
Text & Data Mining in Drug Discovery: A Conversation with Springer Nature
Hear Mark Davies, SVP Informatics and Data, speak to Springer Nature about how BenevolentAI is leveraging the scientific literature to expedite drug discovery.
Sep 2, 2022
News
Notice of Interim Results and Analyst / Investor Event
BenevolentAI will announce interim results on the 27th of September and hold an analyst and investor event on the same day. Find out more.
Aug 26, 2022